Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study

Background. Recombinant T-cell receptor ligand 1000 (RTL1000) is a single-chain protein construct containing the outer two domains of HLA-DR2 linked to myelin-oligodendrocyte-glycoprotein- (MOG-) 35–55 peptide. Analogues of RTL1000 induce T-cell tolerance, reverse clinical and histological disease,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadav, Vijayshree, Bourdette, Dennis N., Bowen, James D., Lynch, Sharon G., Mattson, David, Preiningerova, Jana, Bever, Christopher T., Simon, Jack, Goldstein, Andrew, Burrows, Gregory G., Offner, Halina, Ferro, Al J., Vandenbark, Arthur A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328144/
https://www.ncbi.nlm.nih.gov/pubmed/22548151
http://dx.doi.org/10.1155/2012/954739

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328144/
https://www.ncbi.nlm.nih.gov/pubmed/22548151
http://dx.doi.org/10.1155/2012/954739

Ejemplares similares